stockrowImmunityBio, Inc.
IBRX Healthcare Biotechnology
ImmunityBio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $113.3 million, up 668.3% from fiscal 2024.
- Revenue
- +93.9%
- EPS
- −120.0%
- Free cash flow
- +13.4%
- Total debt
- +57.4%
Quarter to June 2026, against a year earlier
Follow IBRX
Alert me
ImmunityBio, Inc. (IBRX) Shares outstanding
ImmunityBio, Inc.'s shares outstanding at the end of fiscal 2025 was $919.9M, up 31.3% from $700.4M in fiscal 2024. At the end of the quarter to 30 June 2026 it was $1.1B. Over the past ten years it has ranged from $71.5M (fiscal 2015) to $919.9M (fiscal 2025) — the current reading is the highest in ten years. ImmunityBio, Inc. ranks 2nd of 600 Biotechnology companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $919.9M | 31.33% |
| FY2024 | $700.4M | 37.71% |
| FY2023 | $508.6M | 27.19% |
| FY2022 | $399.9M | 2.74% |
| FY2021 | $389.2M | 3.23% |
| FY2020 | $377.1M | 2.93% |
| FY2019 | $366.3M | 362.93% |
| FY2018 | $79.1M | (1.80%) |
| FY2017 | $80.6M | (1.70%) |
| FY2016 | $82.0M | 14.62% |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Jun 2026 | $1.1B | 2.26% |
| Mar 2026 | $1.0B | 11.63% |
| Dec 2025 | $919.9M | (2.82%) |
| Sep 2025 | $946.6M | 6.57% |
| 42 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| IBRX ImmunityBio, Inc. | $1.1B |
| CAI Caris Life Sciences,�Inc. compare | $295.1M |
| TGTX TG Therapeutics, Inc. compare | $157.3M |
| CYTK Cytokinetics, Incorporated compare | $132.1M |
| SYRE Spyre Therapeutics, Inc. compare | $88.4M |
| PTGX Protagonist Therapeutics, Inc. compare | $71.0M |
| TWST Twist Bioscience Corporation compare | $62.4M |
| KRYS Krystal Biotech, Inc. compare | $30.8M |
| MDGL Madrigal Pharmaceuticals, Inc. compare | $30.3M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on IBRX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement